Bayer Files For Additional Indication Of Adempas For PAH In Japan
This article was originally published in PharmAsia News
Executive Summary
Bayer has filed an application in Japan for the additional indication of its chronic thromboembolic pulmonary hypertension drug Adempas (riociguat) for pulmonary arterial hypertension treatment, the company announced on April 23.